Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412009 | PMC |
| http://dx.doi.org/10.5826/dpc.1303a154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module.
Acta Pharmacol Sin
December 2024
Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning, 530021, China.
Small cell lung cancer (SCLC) is a recalcitrant malignancy with dismal prognosis due to rapid relapse after an initial treatment response. More effective treatments for SCLC are desperately needed. Our previous studies showed that cell migration-inducing hyaluronan binding protein (CEMIP) functionally promotes SCLC cell proliferation and metastasis.
View Article and Find Full Text PDFRemission of refractory esophageal lichen planus induced by tofacitinib.
Z Gastroenterol
September 2024
Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Article Synopsis
- There is currently no established treatment for Eosinophilic Lichen Planus (ELP), and standard therapies for cutaneous Lichen Planus (LP), like retinoids, are ineffective in ELP cases.
- Topical glucocorticosteroids can help in some cases of esophageal inflammation but are not always effective, leading to the trial of various immunosuppressive therapies with mixed results.
- The report highlights a severe ELP case that was resistant to multiple treatments, but significant improvement was achieved with the JAK inhibitor tofacitinib, suggesting its potential role in treating this immune-mediated condition.
Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies.
J Ophthalmic Inflamm Infect
March 2024
Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Article Synopsis
- Ocular inflammatory diseases like scleritis and uveitis are treated with immunomodulatory therapies (IMTs) to reduce reliance on steroids, using both conventional and biologic agents, including cyclophosphamide (CP), an effective but potentially harmful treatment option.
- A study reviewed the medical records of 1295 patients at Stanford’s Uveitis Clinic from 2017 to 2022, focusing on 7 patients who received CP therapy for severe ocular inflammatory diseases that didn’t respond to other IMTs.
- The average age of these patients was 61.6 years, with various underlying conditions, and after a mean follow-up of 34.4 months on CP therapy,
Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum.
Front Med (Lausanne)
October 2023
Serviço de Imunologia, Hospital Universitário Prof. Edgar Santos, Universidade Federal da Bahia, Salvador, Brazil.
Chronic recalcitrant erythema nodosum leprosum (ENL) or type 2 reaction (T2R) is a severe condition found in approximately 50% of multibacillary leprosy subjects. T2R is associated with important morbidities and may lead to several disabilities, not only due to nerve damage but also due to the prolonged use of corticosteroids, thalidomide, or immunosuppressors. We describe here four leprosy patients with chronic recalcitrant ENL treated with cyclophosphamide pulse therapy.
View Article and Find Full Text PDFSinus histiocytosis or Rosai-Dorfman disease (RDD) is a rare disorder with severe lymphadenopathy and a limited clinical course, the aetiology of which is still controversial. The disease usually affects cervical nodes, with fever, polyclonal gammopathy, and leucocytosis with neutrophilia. Pure cutaneous involvement occurs as the only manifestation in only 3% of cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!